According to a new study, patients of COVID-19 who are hospitalized and are taking a low-dose of aspirin daily are at an advantage to fight the infection. The medication taken for protection against cardiovascular disease reduces risk of complications and death from the infection significantly, than for those not taking the medicine, says a study led by researchers at the Maryland School of Medicine.
Patients who were taking aspirin were less likely to be placed in intensive care unit (ICU) or hooked up to a mechanical ventilator. And, these patients were more likely to pull through the infection when compared to hospitalized patients who were not on the medicine.
Termed as ‘cautious optimism’, the phenomenon is published in the journal Anesthesia and Analgesia. It provides an inexpensive, accessible medication with a well-known safety profile that could help prevent severe complications.
Finding needs to be established through Random Clinical Trials
“The finding is critical and needs to be confirmed through random clinical trial,” said the study leader. In the even the finding is confirmed, aspirin would be the first, over-the-counter medication for decline in mortality of COVID-19 patients.
For the study, the team scanned the medical records of 412 patients with COVID-19 with an average age of 55 years, and who were hospitalized due to complications of their infection. Another common aspect of these patients is that received treatment at the University of Maryland Medical Center, Baltimore and three other hospitals on the East Coast. Among the select number of patients, about one-fourth were taking a low-dose of aspirin before admitted to the hospital, or right after admission to manage their cardiovascular disease.
According to the finding, aspirin use was associated with a reduction of about 44 percent of risk of using mechanical ventilator for patients.